SP09253 / Hefei Shengpu Pharmaceutical - LARVOL DELTA

SP09253, an orally bioavailable, highly potent RAS(ON) molecular glue inhibitor demonstrates robust anti-tumor activity in KRAS-mutant tumors (AACR 2026) - "SP09253 potently inhibits ERK phosphorylation and cellular viability in KRAS mutantt cell lines in vitro. SP09253 demonstrates robust in vivo efficacy in KRAS mutant xenografts harboring different mutant types, including G12C, G12D, G12V, etc., while showcasing a favorable PK profile and oral bioavailability."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS